MoonLake Immunotherapeutics vs MediciNova, Inc. — Valuation Comparison 2026
Access all valuation models for MLTX vs MNOV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →MNOV scores higher with a 6.2/10 quality rating vs MLTX's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing MoonLake Immunotherapeutics (MLTX) and MediciNova, Inc. (MNOV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
MLTX currently trades at $18.68 with a QOC of 4.0/10, while MNOV trades at $1.37 with a QOC of 6.2/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).